Amferia signs major animal health contract with Biokema and expands into Switzerland
Swedish medtech company Amferia, with a mission to combat infections globally, announces the signing of its second commercial agreement. The contract is with the leading Swiss animal health company Biokema SA for commercialization of Amferia’s proprietary wound care technology for Animal Health in Switzerland — a wound dressing for animals that kills bacteria even resistant bacteria.
Anand Rajasekharan, CEO of Amferia — “Biokema’s market leadership in animal health will spearhead Amferia’s vision of reducing antibiotic resistant wound infections in animal health in Switzerland. We are inspired by this partnership, which will bring our innovation together with a leading distributor to a market where there is considerable need for improved and cost effective solutions. Amferia’s innovation has already received strong interest and positive feedback from veterinarians from across Europe, who immediately notice the potential of our new proprietary antimicrobial material within wound and infection management.”
The joint partnership with Biokema will enable Amferia’s technology to reach veterinary patients in Switzerland where wound care and infection prevention is of prime importance. With the growing threat of antibiotic resistant infections globally, Amferia and Biokema’s partnership will build on extensive data collection and feedback from Amferia’s clinical testing across Europe, including Switzerland. The joint efforts aim to market the products starting early 2025.
Dr. Julia Golaz, Commercial Director of Biokema — “ Rapidly providing innovative therapeutic solutions to veterinarians is a priority challenge for Biokema. The partnership with Amferia will allow us to offer to Swiss veterinarians a new technology to reduce antibiotic-resistant wound infections and antibiotic use.
Biokema thus continues to be part of the strategy on antibiotic resistance, essential to sustainably preserve the effectiveness of antibiotics and once again demonstrates its commitment to veterinarians for better care of animals. We are delighted with this partnership with Amferia, based on a shared vision and motivation.”
For more information, please contact:
Anand Kumar Rajasekharan, CEO, Amferia AB, anandk@amferia.com, +46 (0) 76 298 12 38.
Dr. Julia Golaz, Commercial Director, Biokema SA, jgolaz@biokema.ch, + 41 (0) 79 815 86 47
About Amferia
Amferia's antimicrobial amphiphilic hydrogel kills bacteria, even resistant bacteria without harming the body. The material was developed through several years of research in collaboration with Chalmers University of Technology and the first product from this technology platform is a wound-care dressing for dry-to-low exuding wounds. Amferia's innovative, anti-microbial solution can be used on wide-ranging wounds from simple skin injuries, post-operative wounds to chronic wounds and trauma / burn wounds. The WHO predicts that antibiotic-resistant infections, including those from wounds could become one of the leading causes of both illness and death over the next ten years. Amferia is committed to further research and development to expand the applications of its hydrogel technology. The company aims to improve infection control and patient outcomes across various medical fields. Today, Amferia has ongoing clinical investigations in Europe and is seeking CE marking and FDA clearance for human application. The company signed its first commercial agreement with Orkla Wound Care during the second quarter of 2023. The proprietary material is being investigated for continuous development in several other areas, including sprays for deep wounds, and coatings for implants and a variety of catheters. Read more about the products, team, technology and publications at www.amferia.com.
About Biokema
Biokema SA, founded in 1959, is a Swiss company specializing in the supply of pharmaceuticals and veterinary products. Entirely owned by Swiss shareholders, Biokema SA focuses on delivering its own brands while also partnering with international leaders in animal nutrition and veterinary medical devices. With a constantly evolving product portfolio, recognized technical expertise, and customer relationships built on a strong history and trust, Biokema SA has established itself as an essential partner in veterinary medicine.
